aptaTargets has reported the dosing of the first subject in a Phase Ib clinical trial of its drug, ApTOLL, to treat Covid-19 patients admitted to the hospital.
The first subject was dosed at the University Hospital La Princesa in Madrid, Spain.
Named aptaCovid, the blind, randomised, multicentre, placebo-controlled trial will enrol 30 Covid-19 patients admitted to the hospital and are at cytokine storm syndrome development risk.
Cytokine storm syndrome is an uncontrolled inflammatory process of the ailment.
Analysing the safety and efficacy of ApTOLL is the aim of the trial.
The trial was also launched at three other Spanish hospitals, Ramón y Cajal, Clínico San Carlos of Madrid and the University Hospital of Burgos.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Subjects in the trial will be given three intravenous drug doses for three days and their clinical progress and inflammatory process development will be evaluated.
The company anticipates reporting the initial data from the trial in the third quarter of this year.
On obtaining positive findings, aptaTargets will progress ApTOLL to Phase II trials.
Last year, the Spanish Agency of Medicines and Medical Products (AEMPS) granted clearance to commence the trial, which also obtained funds from the Spanish Ministry of Science and Innovation agency and the Centre for the Development of Industrial Technology.
aptaTargets CEO David Segarra said: “We are very happy that this aptaCovid trial has included the first patient and that it is taking place at leading hospitals in infectious diseases.
“ApTOLL offers high potential to be an effective and safe treatment option in patients hospitalised for Covid-19.”
In February this year, the company joined a consortium to advance ribonucleic acid oligonucleotide-based therapy development for treating rare diseases.